Results 311 to 320 of about 362,523 (334)
Some of the next articles are maybe not open access.
Durvalumab Promising for NSCLC
Cancer Discovery, 2017Abstract The PD-L1 inhibitor durvalumab increases progression-free survival and objective response rate in patients with inoperable and locally advanced stage III non–small cell lung cancer, according to interim results of a phase III trial. The benefit was great enough that the drug could become the standard of care in the United States
openaire +2 more sources